Publications

Publications

320 publications

Enter search criteria

Fill in keyword(s) to narrow your search.

Period from
to

Enter a start and/or end date here, using the following format: DD-MM-YYYY.

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by: Date / Relevance

GVS advice SGLT-2 inhibitors

Zorginstituut Nederland has completed its assessment the further conditions of SGLT-2 inhibitors canagliflozin (Invokana®), ...

Report | 22-06-2021

GVS advice RZV (Shingrix®) for the prevention of herpes zoster and related post-herpetic neuralgia

Zorginstituut Nederland has completed its assessment whether the recombinant herpes zoster vaccine with adjuvant (RZV, Shingrix®) ...

Report | 14-06-2021

GVS advice avatrombopag (Doptelet®) for the treatment of thrombocytopenia

Zorginstituut Nederland has completed its assessment whether avatrombopag (Doptelet®) is interchangeable with a product that is ...

Report | 08-06-2021

GVS advice Vocabria® and Rekambys® for the treatment of HIV-1 infection

Zorginstituut Nederland has completed its assessment whether the products Rekambys® and Vocabria® can be included in the ...

Report | 08-06-2021

GVS advice ivacaftor (Kalydeco®) extension of further conditions

Zorginstituut Nederland carried out a review to extend the further conditions for reimbursement of ivacaftor (Kalydeco®). The ...

Report | 25-05-2021

Package advice pertuzumab and trastuzumab (Phesgo®) for the treatment of breast cancer

Zorginstituut Nederland has completed its assessment whether the fixed combined dose of pertuzumab and trastuzumab (Phesgo®) can ...

Report | 11-05-2021

Package advice onasemnogene abeparvovec (Zolgensma®) for the treatment of SMA

Zorginstituut Nederland has completed its assessment whether onasemnogene abeparvovec (Zolgensma®) for the treatment of patients ...

Report | 06-05-2021

GVS advice inclisiran (Leqvio®) for the treatment of hypercholesterolemia

Zorginstituut Nederland has completed its assessment whether inclisiran (Leqvio®) is interchangeable with a product that is ...

Report | 04-05-2021

GVS assessment of trientine dihydrochloride (Cufence®) for the treatment of Wilson’s disease

Zorginstituut Nederland has completed its assessment whether trientine dihydrochloride (Cufence®) can be included in the Medicine ...

Report | 19-04-2021

GVS assessment of crisaborole (Staquis®) for the treatment of atopic dermatitis

Zorginstituut Nederland has completed its assessment whether crisaborole (Staquis®) is interchangeable with a product that is ...

Report | 15-04-2021